Mirxes
Mirxes is a Singapore-based RNA diagnostics company that develops proprietary blood-based miRNA test kits — including GASTROClear and LUNGClear — for early cancer detection, serving hospitals, clinics, oncology providers, and research institutions across Asia Pacific.
- Company typePublic
- Founded2014
- HeadquartersSingapore, Singapore
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mirxes does
Mirxes is a Singapore-headquartered RNA diagnostics company founded in 2014 and listed on the Hong Kong Stock Exchange (ticker hkg:2629), specialising in blood-based microRNA tests for early cancer detection. Its core technology is the proprietary ID3EAL RT-qPCR platform, which underpins GASTROClear — the world's first molecular blood test for gastric cancer screening, detecting 12 miRNA biomarkers with 87% sensitivity — and LUNGClear for early-stage lung cancer detection. The portfolio extends to NGS-based cancer treatment selection panels (APEX Tissue with 58 genes; COMPASS Tissue with 1,021 genes), precision multiomics research services (spatial transcriptomics, single-cell sequencing, WGS/WES, RNA-Seq, methylation), the Cryomics biobanking service, and Fortitude RT-PCR infectious-disease kits.
Mirxes operates a hybrid business model spanning clinical diagnostic services through its wholly owned M Diagnostics laboratory, sales of diagnostic test kits and reagents to hospitals and laboratories, research and bioinformatics services to pharmaceutical and academic clients, and biobanking managed services. Commercialisation follows a regulatory-led go-to-market: GASTROClear has secured FDA Breakthrough Device Designation, CE Mark, Singapore HSA Class C IVD approval, and China NMPA approval, and is sold through a network of over 200 clinics and hospitals in Singapore — anchored by NUH, Tan Tock Seng, SGH, NCCS, and Raffles Medical — alongside distribution in six Asia Pacific markets and a recently opened China commercial operation. Operations span Singapore (HQ, manufacturing, R&D, and clinical lab), Hangzhou, Tokyo, and Cambridge, MA, with an emerging agentic AI clinical decision-support capability built on Oracle Cloud Infrastructure.
Mirxes is led by Co-founder and CEO Dr. Zhou Lihan, with Co-founder Prof. Too Heng-Phon as Chief Scientific Advisor and Non-Executive Chairman; the management bench was expanded with appointments including a Chief Investment Officer and Chief Financial Officer ahead of the May 2025 IPO that raised HK$1.09 billion and made the company Southeast Asia's first biotech unicorn.
Mirxes firmographics
Firmographics- Name
- Mirxes
- Legal name
- Mirxes Holding Pte. Ltd.
- Website
- https://mirxes.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Mirxes is a Singapore-based RNA diagnostics company that develops proprietary blood-based miRNA test kits — including GASTROClear and LUNGClear — for early cancer detection, serving hospitals, clinics, oncology providers, and research institutions across Asia Pacific.
- Ownership category
- akta.pro rank
Mirxes industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Mirxes is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices8 records
Markets served
Mirxes business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Diagnostic Services: Mirxes provides clinical testing services through its M Diagnostics laboratory, offering molecular diagnostic tests for cancer early detection and treatment selection. Services include GASTROClear testing, NGS-based tumor profiling, and other clinical sequencing services.
- Diagnostic Test Kits: Sale of diagnostic test kits including GASTROClear, LUNGClear, Fortitude Kit 2.1 (RT-PCR test for SARS-CoV-2), and RNA extraction kits. Products are sold to hospitals, clinics, and laboratories.
- Research and Precision Multiomics Services: Genomics and bioinformatics services including Stereo-seq spatial transcriptomics, single-cell sequencing, WGS, WES, RNA-Seq, and methylation sequencing for research and discovery purposes.
- Biobanking Services: Cryomics biobanking solutions for secure storage of biological samples and consultancy services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Public sector patients may benefit from more than 50% cost reduction compared to sending samples overseas for APEX NGS testing |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Mirxes product offering
Product offeringCore offering
Mirxes develops and commercializes proprietary RNA-based diagnostic test kits and clinical services for early cancer detection, built on its miRNA biomarker technology platform. Its flagship product, GASTROClear, is the world's first molecular blood test for early detection of gastric cancer using 12 miRNA biomarkers, complemented by LUNGClear for lung cancer, NGS-based APEX Tissue and COMPASS Tissue panels for cancer treatment selection, and Fortitude infectious disease RT-PCR kits. The company also operates clinical diagnostic services through its M Diagnostics laboratory and offers Precision Multiomics research services and Cryomics biobanking.
Product overview
Mirxes offers a portfolio of RNA-based diagnostic products and services centered on its proprietary miRNA technology platform. The core offerings include GASTROClear (world's first molecular blood test for gastric cancer detection) and LUNGClear (lung cancer blood test), both leveraging the ID3EAL Suite RT-qPCR technology. For cancer treatment selection, the company provides APEX Tissue (58-gene NGS panel) and COMPASS Tissue (1,021-gene NGS panel). The portfolio extends to infectious disease testing (Fortitude COVID/Flu tests), precision multiomics research services (spatial transcriptomics, single-cell sequencing, WGS/WES), and biobanking through Cryomics. The company operates clinical studies including CADENCE (multi-cancer early detection for 9 cancer types) and ELEGANCE (liver cancer detection), with an agentic AI assistant for clinical decision support. The platform spans cancer screening, treatment selection, and research solutions.
Differentiator
Problem solved
Functional benefit
Brands
- GASTROClear: World's first molecular blood test for early detection of gastric cancer, detecting 12 gastric cancer-associated miRNA biomarkers.
- LUNGClear
- APEX Tissue
- COMPASS Tissue
- Fortitude Kit 2.1
- ID3EAL Suite
- Cryomics
- Project CADENCE
Products and services
- GASTROClear The world's first molecular blood test for early detection of gastric (stomach) cancer, detecting 12 gastric cancer-associated miRNA biomarkers using RT-qPCR technology with 87% sensitivity. For adults aged 40+ at elevated risk (family history, H. pylori, chronic gastritis, dietary risk factors).
- LUNGClear Minimally invasive blood test designed to identify lung cancer at an early stage, leveraging Mirxes' proprietary miRNA technology platform for early detection in high-risk individuals.
- APEX Tissue Targeted 58-gene Next-Generation Sequencing (NGS) profiling test for cancer treatment selection. Identifies genetic alterations in tumors that may respond to specific targeted therapies, with results delivered in 8 working days at 50%+ cost reduction versus overseas testing.
- COMPASS Tissue Comprehensive 1021-gene profiling test using NGS for personalized treatment decisions across multiple solid tumor types, enabling broad genomic profiling for oncology therapy selection.
- ID3EAL Suite Proprietary RT-qPCR technology platform enabling class-leading, highly sensitive detection of microRNAs, forming the foundation for Mirxes' diagnostic assays and offered as a standalone technology platform.
- Fortitude Kit 2.1 Multiplex RT-PCR test for SARS-CoV-2 detection, a proven testing solution developed during the COVID-19 pandemic.
- Fortitude SARS-CoV-2 & FluA/B Test RT-PCR kit for simultaneous detection of SARS-CoV-2 and Influenza A/B viruses, sold to clinical laboratories and healthcare providers.
- Precision Multiomics Genomics and bioinformatics services including Stereo-seq spatial transcriptomics, single-cell whole genome sequencing, WGS, WES, RNA-Seq, methylation sequencing, and shotgun metagenomic sequencing for research and discovery.
- Cryomics Biobanking solutions offering secure storage and consultancy services for biological samples, operated as a partnering discovery service by Mirxes.
- RNA Extraction Kits & Instruments RNA swab and saliva sample collection kits along with molecular and COVID-19 RNA extraction kits and instruments for use by clinical and research laboratories.
Quantifiable outcome
- 87% sensitivity for early-stage gastric cancer detection (Stage I: 87.5%, Stage II: 89.5%)
- +4 more outcomes
Companies that use Mirxes
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
Mirxes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Mirxes partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and exploratory.
- OraclecoreMirxes is piloting an agentic AI clinical assistant built using Oracle AI Database and Oracle Cloud Infrastructure. The system uses semantic search and retrieval-augmented generation to deliver near real-time responses to clinician queries.
- Singapore Gastric Cancer Consortium (SGCC)coreMulti-institutional consortium including leading Singapore healthcare institutions for gastric cancer research, early detection development, and clinical validation of GASTROClear.
- China National Medical Products Administration (NMPA)coreRegulatory approval body that granted approval for GASTROClear commercialization in China, enabling market access in one of the world's largest gastric cancer markets.
- PULSE TCMexploratoryMirxes and PULSE TCM launched the 'East Meets West' Community Health Screening Pilot, combining Western precision diagnostic technology (GASTROClear) with Eastern TCM preventive medicine approaches for holistic health screening.
- National University Hospital (NUH)coreNUH and Mirxes established NUH DMOC@Biopolis, one of Singapore's first public-private partnership centers for specialty molecular testing. The center integrates NUH's Diagnostic Molecular Oncology Centre (DMOC) with Mirxes' clinical laboratory, combining clinical expertise with cutting-edge molecular testing infrastructure.
- Agency for Science, Technology and Research (A*STAR)coreA*STAR spinoff with research collaboration through Bioprocessing Technology Institute (BTI), Diagnostics Development Hub (DxD Hub), and ecosystem partners. GASTROClear was developed through a seven-year public-private partnership with A*STAR institutions.
- National Cancer Centre Singapore (NCCS)coreLead institution for ELEGANCE study on early detection of hepatocellular carcinoma (HCC). Multi-center collaboration involving leading healthcare institutions for liver cancer detection using miRNA biomarkers.
- National University of Singapore (NUS)coreResearch collaboration with NUS Yong Loo Lin School of Medicine, including the Singapore Gastric Cancer Consortium (SGCC), NUS Centre for Cancer Research (N2CR), and clinical studies at NUH.
- Yonsei Cancer Center (Korea)coreInternational clinical collaboration for GASTROClear validation, conducting large prospective clinical trials involving over 9,000 patients in China alongside seven academic clinical institutions.
Scale indicators11 records
Recent moves9 records
Expansion highlights6 records
Mirxes competitors and assessment
Company assessmentDirect peers
- GRAIL: US-based multi-cancer early detection company (an Illumina subsidiary) commercializing the Galleri blood test that screens for multiple cancers from a single draw. Closest direct competitor to Mirxes' CADENCE multi-cancer screening platform in terms of clinical ambition and regulatory pathway.
- Guardant Health: US-based precision oncology company offering blood-based liquid biopsy tests for tumor profiling and minimal residual disease. Mirxes' APEX and COMPASS NGS tissue panels compete in adjacent oncology molecular diagnostic indications, with Mirxes' miRNA-first approach offering a differentiated biomarker strategy.
- Genetron Health: China-based precision oncology company offering NGS-based tumor profiling and early screening services. Direct peer in the Chinese oncology diagnostics market, particularly for NGS tumor profiling panels similar to APEX/COMPASS.
- Exact Sciences: US-based developer of non-invasive cancer screening and molecular diagnostic tests, including the Cologuard colorectal screening test and an emerging multi-cancer early detection program. Mirxes competes most directly via GASTROClear and CADENCE for non-invasive, blood-based cancer screening positioning.
- Burning Rock Biotech: China-based NGS-based cancer therapy selection company. Direct peer in the Chinese oncology molecular diagnostics market where Mirxes is now entering via NMPA-approved GASTROClear and is positioned to introduce APEX/COMPASS tumor profiling tests.
- New Horizon Health (诺辉健康): China-based early cancer screening company (HKEX-listed) commercializing non-invasive screening tests including ColoClear for colorectal cancer. Most direct Asia peer in blood/stool-based early cancer detection consumer and clinical markets.
- Novogene: China-headquartered genomics services provider offering WGS, WES, RNA-Seq, and single-cell sequencing for research customers. Direct peer in Mirxes' Precision Multiomics service line (Stereo-seq, scWGS, WGS/WES, methylation sequencing), competing for the same APAC research and pharma customers.
Emerging players
- Personalis: US-based cancer genomics company developing ultra-sensitive NGS tests for tumor profiling and neoantigen detection. Comparable peer in next-generation tumor profiling approaches, though operating at earlier commercial scale than Foundation Medicine.
Broad incumbents
- Foundation Medicine: US-based NGS tumor profiling leader (Roche subsidiary) offering FoundationOne CDx and FoundationOne Liquid CDx. Broad incumbent in the comprehensive genomic profiling market that Mirxes' COMPASS Tissue panel competes against, especially in oncology treatment selection.
- Natera: US-based cell-free DNA testing company with Signatera MRD test and growing oncology franchise. Comparable peer in liquid biopsy oncology applications, with broader reproductive testing portfolio but overlapping oncology molecular diagnostic capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Mirxes social profiles
Digital presenceMirxes compliance and trust
Trust signalCompliance7 records
Mirxes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mirxes leadership team
Management profileNumber of profiles
Profiles6 records
Mirxes subsidiaries and ownership
Company hierarchySubsidiaries3 records
Mirxes funding detail
Funding detailFunding overview
Funding rounds6 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mirxes M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mirxes
What does Mirxes do?
Mirxes develops and commercializes proprietary RNA-based diagnostic test kits and clinical services for early cancer detection, built on its miRNA biomarker technology platform. Its flagship product, GASTROClear, is the world's first molecular blood test for early detection of gastric cancer using 12 miRNA biomarkers, complemented by LUNGClear for lung cancer, NGS-based APEX Tissue and COMPASS Tissue panels for cancer treatment selection, and Fortitude infectious disease RT-PCR kits. The company also operates clinical diagnostic services through its M Diagnostics laboratory and offers Precision Multiomics research services and Cryomics biobanking.
Is Mirxes a public or private company?
Mirxes is a public company. It is classified as public and is currently operating.
When was Mirxes founded?
Mirxes was founded in 2014. It employs 101 to 250 people.
Where is Mirxes based?
Mirxes is headquartered in Singapore, Singapore, in the Asia region.
How does Mirxes make money?
Four revenue lines are on record. Clinical Diagnostic Services are the primary driver. The others are diagnostic Test Kits, research and Precision Multiomics Services and biobanking Services.
Who are Mirxes's main competitors?
Direct peers on record are GRAIL, Guardant Health, Genetron Health, Exact Sciences, Burning Rock Biotech, New Horizon Health (诺辉健康) and Novogene. Personalis is listed as an emerging player. Broad incumbents are Foundation Medicine and Natera.
Does Mirxes have an API?
No public API is recorded for Mirxes.
What industry is Mirxes in?
Mirxes's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 325413 and its SIC code is 2835.